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Principles of Educational Outreach('Academic Detailing') to Improve
Clinical Decision Making
Stephen B. Soumerai, ScD, Jerry Avorn, MD
With the efficacy and costs of medications rising rapidly, it is increasingly
important to ensure that drugs be prescribed as rationally as possible. Yet,
physicians' choices of drugs frequently fall short of the ideal of precise and cost\x=req-\
effective decision making. Evidence indicates that such decisions can be im-
proved in a variety of ways. A number of theories and principles of communica-
tion and behavior change can be found that underlie the success of
pharmaceutical manufacturers in influencing prescribing practices. Based on
this behavioral science and several field trials, it is possible to define the theory
and practice of methods to improve physicians' clinical decision making to
enhance the quality and cost-effectiveness of care. Some of the most important
techniques of such "academic detailing" include (1) conducting interviews to
investigate baseline knowledge and motivations for current prescribing patterns,(2) focusing programs on specific categories of physicians as well as on their
opinion leaders, (3) defining clear educational and behavioral objectives, (4)
establishing credibility through a respected organizational identity, referencing
authoritative and unbiased sources of information, and presenting both sides of
controversial issues, (5) stimulating active physician participation in educational
interactions, (6) using concise graphic educational materials, (7) highlighting and
repeating the essential messages, and (8) providing positive reinforcement of
improved practices in follow-up visits. Used by the nonprofit sector, the above
techniques have been shown to reduce inappropriate prescribing as well as
unnecessary health care expenditures.
(JAMA. 1990;263:549-556)
THE HIGH cost of medical care and
increasing concern about appropriate
use of medical technology have resulted
in a new wave of interest in how physi¬
cians can be encouraged to make more
accurate and cost-effective clinical deci-
sions. Some efforts have emphasized re¬
strictions and economic disincentives,
but evidence is emerging that in some
applications such strategies may threat¬
en the quality ofcare at least as much as
they reduce expenditures.1,2 Continuing
education has received much less atten¬
tion as a means of behavior change, per¬
haps because it often is ineffective in
this regard.3
University-based educational out-
reach (sometimes known as "public in¬
terest detailing" or "academic detail¬
ing") is a newer approach that has been
evaluated as part of a four-state ran¬
domized, controlled trial.4"7 Prescribing
problems that could be targetedby such
approaches include use of drugs with
low benefit/risk ratios when safer alter¬
natives are available, use of ineffective
or marginal therapies for treatable con¬
ditions, use of excessive numbers of
medications in vulnerable populations(eg, children and the elderly), use of
high-cost agents when less expensive
medications would work as well, and
underuse of effective agents for major
illnesses (eg, hypertension in the elder¬
ly).5 In one study of educational out¬
reach, two brief visits to physicians by
clinical pharmacists trained in effective
techniques of communication and per¬
suasion as well as pharmacotherapy
were found to reduce inappropriate pre¬
scribing of cerebral vasodilators, cepha-
lexin, and propoxyphene by 14% in com¬
parison with controls (P=.0001).4 A
formal economic analysis of these find¬
ings estimated benefits (reductions in
unnecessary expenditures) and costs of
the intervention and considered stabil¬
ity ofeffects over time, use of substitute
medications, targeting ofhigh prescrib-
ers, and quality effects.6 The data indi¬
cated that an operational-scale program
would produce savings two to three
times greater than the costs of mount¬
ing such a program, without counting
improvements in the quality of care. A
follow-up analysis7 indicated that while
physician characteristics such as age,
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board certification, and specialty did
not affect response to the educational
intervention, a second reinforcement
visit substantially increased compliance
with prescribing recommendations.
Other controlled studies also have docu¬
mented the effectiveness and receptiv¬
ity ofphysicians to face-to-face counsel¬
ing.5,8"10 This article discusses the
principles and techniques of such ap¬
proaches to physician behavior change.
The prescribing of drugs has served
as a useful model for studying ways of
improving the accuracy of physician de¬
cision making. Problems of misutiliza-
tion of drugs stem from many sources,
only some ofwhich relate to the pharma¬
ceutical industry.5 Nonetheless, the in¬
dustry's marketing strategies may
serve as an instructive model (both good
and bad) for those interested in improv¬
ing the rationality of clinical decision
making. Detailing, the promotional ac¬
tivities of pharmaceutical company
sales representatives, accounted for
more than half of the estimated $3 bil¬
lion spent annually on promotion by US
pharmaceutical companies in the early
1980s (Wall Street Journal. May 25,
1984:31, 49).11 Pharmaceutical repre¬
sentatives have been operating for
more than 100 years and number about
28 000 in the United States alone (Wall
Street Journal. May 25, 1984:31, 49),12
or approximately one representative
for every 10 office-based practitioners.13
At least $5000 is spent per physician
each year in support of detailing activi¬
ties, excluding journal and direct mail
advertising expenditures (Wall Street
Journal. May 25, 1984:31, 49).n"13 The
detailer/physician ratio is even higher in
some other western countries, approxi¬
mating 1:3 in Brazil and 1:4 in Mexico.14
One form of evidence for the effec¬
tiveness of these traveling personnel is
that pharmaceutical companies contin¬
ue to invest such large sums ofmoney in
this approach, based on their own cost-
benefit calculations. Several studies in¬
dicate that for many physicians, the de-
tailer is generally the first source of
information about new therapies.15 In¬
deed, even when commercial messages
on product efficacy differ markedly
from objective, scientific sources of in¬
formation, the beliefs concerning sever¬
al drugs of a large, randomly selected
sample of primary care physicians cor¬
responded more closely to the commer¬
cial information.16 Despite the fact that
detailers shape so much prescribing be¬
havior, there is little in the scientific
literature about the techniques or ap¬
proach of these representatives and
how they might be adapted to reduce
inappropriate prescribing. The few
studies that do exist14,17 simply describe
the broadly defined components of sales
presentations, as derived from survey
information.
The following analysis of common
techniques and principles employed by
such change-agents are based on in-
depth interviews with and videotapes
of former pharmaceutical representa¬
tives, other written accounts of the de¬
tailing process, and our own experience
in mounting several trials of "public in¬
terest detailing" in five states to reduce
excessive or inappropriate prescrib¬ing.4"710 As discussed below, these tech¬
niques are also based on research in the
fields ofadult learning, diffusion of inno¬
vations, and persuasive communica¬
tion.
BEHAVIOR CHANGE
STRATEGIES
The effectiveness of the commercial
detail visit is the result ofmore than 100
years of sales experience. Generally
lasting less than 10 minutes, the presen¬
tation is likely to contain several effec¬
tive strategies for behavior change that
serve to reinforce and complement one
another.1819 Some similarities exist be¬
tween pharmaceutical marketing goals
and several objectives of nonprofit or¬
ganizations. For example, clinical de¬
partment chairpersons, quality assur¬
ance staff, and health care administra¬
tors and payers would like to encourage
prescribing behavior that would contain
costs without sacrificing quality of care
and, ideally, would improve it. In previ¬
ous studies the use of inexpensive but
effective antibiotics has been promoted
to replace costly cephalosporins in
the treatment of uncomplicated infec¬
tions4,6 ,7,9; the use of potentially danger¬
ous antibiotics to treat minor infections
in ambulatory practice has been cur¬
tailed (eg, chloramphenicol for viral up¬
per respiratory tract infections)9; and
safe and effective over-the-counter an¬
algesics, such as aspirin, have been sub¬
stituted for less effective and potential¬
ly problematic prescription drugs such
as propoxyphene.6 Other interventions
have focused on the way a drug is pre¬
scribed; for example, certain effective
drugs are prescribed too frequently or
in excessive dosages, causing unneces¬
sary risks of adverse drug reactions and
increased costs.20,21 While important dif¬
ferences exist between pharmaceutical
marketing and medical education or
quality assurance, there is reason to be¬
lieve that many of the techniques de¬
scribed below could be adapted to such
purposes. Our goal is to identify those
aspects of detailing that can be put in
the service of supporting the physician
in making better therapeutic decisions,
while leaving aside any techniques that
might be manipulative or serve only to
increase sales ofa given product.
Defining Specific Problems
and Objectives
A key first step in any program to
influence clinical decision making is to
define the area(s) to be addressed and
the specific behaviors to be encouraged
or discouraged. Such agenda setting is
more straightforward in the pharma¬
ceutical industry, where the fiscal "bot¬
tom line" is, by definition, the outcome
ofconcern and increasing sales of specif¬
ic branded products is the means toward
that end. Sponsors of other progams
face more complicated choices. For a
nonprofit health maintenance organiza¬
tion, employer, or insurer responsible
for all aspects of medical care, the out¬
come ofconcern may be the highest pos¬
sible quality of care at the lowest possi¬
ble cost—goals that may conflict and
that often cut across multiple categories
of service (eg, drugs, hospitalization,
and physician visits may all be affected
by use of histamine antagonists). It
therefore is necessary to begin by iden¬
tifying the specific cases ofpractice that
are ofhighest concern in terms of quali¬
ty and/or cost and to design a program
that will target these decisions initially,
specifying clear alternatives to be en¬
couraged. For example, Ray et al22 used
Medicaid claims data to identify inap¬
propriate prescribing of tetracycline to
children by general practitioners in
Tennessee. Subsequent educational ef¬
forts focused on the objectives of reduc¬
ing this practice as much as possible
among targeted groups due to the risk
of permanent discoloration of develop¬
ing teeth and substituting safer antibi¬
otics for this population. A secondary(but less measurable) objective was to
reduce prescribing of any antibiotics for
simple upper respiratory tract infec¬
tions.
Market Research
One of the most important lessons
that can be derived from pharmaceuti¬
cal marketing strategy is the need to
understand the motivations that under¬
lie physician use ofa particular product.
One failure of traditional continuing
medical education has been the assump¬
tion that the transmittal of rational in¬
formation alone, independent of how it
is provided, will predictably result in
improved clinical decisions.3 While the
provision of new knowledge and infor¬
mation may be sufficient in some cases,
considerable research has made appar¬
ent the need to consider other "nonsci-
entific" factors such as attitudes toward
particular diseases or patients, habits,
peer influence, patient demand, time
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Fig 1.—Patient education material designed to re¬
duce patient demand for vasodilators for claudica¬
tion. Space for an "exercise prescription" is provided
inside.
constraints in busy office practices, and
economic incentives as prerequisites to
the design of educational messages.523"26
For example, providing more informa¬
tion on the therapeutic efficacy of aspi¬
rin may be irrelevant to the physician
who prescribes prescription analgesics
primarily in response to patient de¬
mands.
Several approaches can be used to
determine physician motivations for
their therapeutic decisions, including
focus group interviews, surveys of pre-
scribers, and ongoing communication
between detailers/educators and physi¬
cians. In focus group interviews,26 the
market researcher assembles a small
group of consumers (in this case, physi¬
cians) and attempts to stimulate a frank
and open discussion of the important
motivations for choosing particular
products over others. On one level, an
attempt is made to identify the major
product characteristics (eg, efficacy or
safety) that physicians value in their
choice of similar products as well as phy¬
sician perceptions of the comparative
advantages and disadvantages of rec¬
ommended vs competitive products.
These factors eventually became major
messages to communicate in face-to-
face details and printed advertisements(eg, the relative efficacy of one product
over another, patient convenience, side
effects profile, and so on).
If the facilitator is sufficiently skilled,
he or she may discover some key non-
clinical motivations that might other¬
wise remain hidden owing to their nega¬
tive social or ethical tint (eg, prescribing
tranquilizers to quiet demented elderly
patients at the request of nursing home
staff). Practice-driven motivations may
cause many physicians, although fully
aware of the pharmacology involved, to
use marginal therapies because of pa¬
tient demand factors or intentional use
of active placebos.23 For this sizable
group, an intervention aimed only at
presenting efficacy data would yield
minimal results. In our prior work, we
instead developed a set of "patient man¬
agement strategies" and education di¬
rected at the patient (Fig 1) to help
these physicians to cope better with in¬
appropriate requests.
The focus group approach may fail if
the group of physician-volunteers (or
paid consultants) sampled is not gener-
alizable to the larger group of practitio¬
ners. To avoid this problem, several
such groups are convened and larger,
structured or unstructured surveys of
more representative samples of target
physicians are conducted before devel¬
opment of program content. Thus, fit¬
ting the relevant information to the val¬
ues, attitudes, and beliefs of practicing
physicians is an ongoing task both in
defining the general content of commu¬
nications in the planning stage and in
the process ofone-on-one education.
Establishing Credibility
Establishing and maintaining a credi¬
ble identity is an essential ingredient in
effective communication. In the phar¬
maceutical industry, credibility is
sought by reference to prestigious clini¬
cal research centers that evaluated the
drug and journals that reported the re¬
search. According to representatives
we interviewed, the "aura" surrounding
identification with clinical trials at such
research centers may contribute as
much to adoption of the drug as the
scientific aspects of the studies. Phar¬
maceutical companies also sponsor sci¬
entific symposia for practicing physi¬
cians to convey product-specific in¬
formation and to enhance the academic
image of the company and its represen¬
tatives, although data suggest that the
content of such symposia occasionally
may be colored by product sales mes-
sages.27,28 Physician awareness of the
profit motive and its potential impact on
the objectivity ofpromotional messages
presents a formidable obstacle for com¬
mercial representatives.
Sponsorship of educational outreach
programs by neutral professional
groups represents a significant advan¬
tage for "nonprofit" detailers. Two tri¬
als of face-to-face prescribing education
utilized the imprimatur of respected
medical organizations, a state medical
society and a medical school drug infor¬
mation program.4,9 Such unbiased orga¬
nizational identities were an important
factor in achieving high rates of physi¬
cian acceptance of the personal visits(92% of physicians randomized to this
group agreed to meet with the medical
school-based "detailer").4 Another im¬
portant aspect of both programs was
their utilization of academically based
educators bringing the latest clinical
findings of importance to the physician's
doorstep. In another setting, the teach¬
ing hospital, credibility also can be dem¬
onstrated through identification with
expert consultants (eg, antibiotic useguidelines approved by the infectious
disease service).20
Targeting 'High-Potential'
Physicians
Pharmaceutical sales representa¬
tives often prioritize their sales calls in
relation to the magnitude of potential
sales to individual physicians.29 These
determinations are made through com¬
pany profiles of physicians' previous
prescribing patterns and other data on
physician specialties and interests.
Thus, a representative can maximize
his potential sales per hour of effort by
spending the most time with physicians
whose total prescribing volumes are
high enough to yield potentially high
sales of the detailer's products or with
physicians who are opinion leaders.
Similarly, from a noncommercial stand¬
point, it makes no economic sense to
blanket all physicians with face-to-face
interventions when many of these phy¬
sicians do not prescribe either inappro¬
priately or in high enough volumes to
yield substantial savings or improve¬
ments in care.
In previous controlled studies of uni¬
versity-based pharmaceutical educa¬
tion for community physicians,4,6,7 9 mod¬
erate- to high-volume prescribers of
target drugs were identified using data
from the Medicaid Management Infor¬
mation Systems in five states. While
physicians reduced excessive prescrib¬
ing to the same degree regardless of
baseline levels of use, the benefit/cost
ratio was the highest (approximately
3:1) in the group with the highest initial
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volume of target drug use.6 As hospi¬
tals, health maintenance organizations,
and other health care organizations con¬
tinue to develop computerized systems
to track resource utilization on a physi¬
cian-specific basis, it will become
increasingly practical to identify physi¬
cians with particular utilization prob¬
lems and present them with focused
educational interventions. However, in
the above studies these data were not
used on an individual basis to feed back
information indicating that particular
physicians were operating outside of es¬
tablished norms. Surveillance and feed¬
back of this sort is another approach
that may work best in certain settings
with established lines of authority (eg,
teaching hospitals and staff model
health maintenance organizations).
Involvement of 'Opinion Leaders'
A key pharmaceutical marketing
strategy is to identify and involve local
physician opinion leaders: those individ¬
uals who tend to be early adopters of
pharmaceutical innovations and impor¬
tant and respected sources of influence
for other physicians in their communi¬
ties. Previous research by Coleman et
al15 documented that a relatively small
proportion of physician leaders are the
most integrated into the medical infor¬
mation network and are also the most
likely to be extremely influential per¬
suaders of other, less-integrated physi¬
cians. Through these informal social
networks, a "contagion" response is
seen after adoption by the opinion lead¬
er, aided by the pharmaceutical repre¬
sentatives who may refer to these re¬
spected peers in their own detailing of
other practitioners. The involvement of
such opinion leaders in the design and
implementation of quality of care or
cost-containment educational interven¬
tions can also increase their effective¬
ness. Stross and Bole30 observed that
surveys of community physicians could
easily identify the most educationally
influential physicians. These individ¬
uals were subsequently enlisted in a
program to upgrade their colleagues'
arthritis treatment decisions during in¬
formal "teachable moments," when
their advice was being sought on related
clinical problems.
Two-Sided Communication
Research has also shown that "inocu¬
lation against counterarguments," or
presenting both sides of an issue, aids
learning, particularly in situations
where the receiver is knowledgeable
about counterarguments.31 If detailers
completely discount the positive attri¬
butes of an alternative product or thera-
peutic approach, their credibility may
be damaged and physicians may even
feel offended that their beliefs and expe¬
riences were treated as invalid. In¬
stead, the detailer is likely to briefly
acknowledge the physician's reasons for
using the competitive drug, often elicit¬
ed by asking him. However, he will then
deemphasize them in comparison with
the advantages of his company's prod¬
uct. For the same reason, the detailer
may briefly mention the disadvantages
of the drug he is promoting—a message
probably communicated already by the
competition in any case. The same prin¬
ciple applies to nonprofit educational ef¬
forts. For example, in our attempts to
persuade physicians at an urban teach¬
ing hospital to substitute gentamicin
when appropriate for tobramycin, we
learned that physicians believed the un¬
substantiated marketing claim that to¬
bramycin was less nephrotoxic than
gentamicin. Rather than ignoring this
important issue (or waiting for physi¬
cians to bring it up), we actively ac¬
knowledged the controversy and pro¬
vided literature references that sup¬
ported the alternative conclusion of no
meaningful difference in nephrotoxi-
city. This process was accomplished in a
tactful manner that did not excessively
criticize these misperceptions.
Promoting Active Learner
Involvement
Successful behavior change often is
dependent on the ability of the educator
to relate the message (or product) to the
beliefs, needs, values, and interests of
the individual physician. Thus, the at¬
tempt to engage the physician in two-
way communication is an important way
of building a physician-specific presen¬
tation32 at the same time as it increases
the involvement of the physician in the
interaction. For example, asking the
physician why he or she uses a given
drug makes it possible to identify and
then target relevant motivations and
clinical circumstances as well as to
gauge the strength of their beliefs.5 In
the commercial setting, this also makes
it possible for manufacturers to use de¬
tailers as sources ofmarketing informa¬
tion, particularly in determining reac¬
tions to products soon after their release
to the market.25 However, detailers are
careful not to overquestion physicians,
as this may lead some physicians to feel
that their time is being wasted or, worse
yet, that the detailer is trying to test or
manipulate them.19 A sales-maximizing
version of some of these principles is
embodied in an article entitled "Credi¬
bility: The Key to Long-term Success,"
which appeared in a publication for
pharmaceutical sales personnel33:
Logical, meaningful questioning is an excel¬
lent way to give you credibility and to get thephysician into a pattern of dialogue and a
mindset towards responding positively to a
closing challenge. Probing will get the physi¬
cian to assimilate the information and require
him to actively follow your thought direction.
As he answers your questions, his thought
will begin to crystallize. Remember, a person
does his best listening when he is talking.
Similarly, a long history of research
and practice in the field of adult learn¬
ing has suggested that stimulating
learner involvement through interac¬
tion achieves a higher likelihood of at¬
taining educational and behavioral ob¬jectives as well as greater satisfaction.34
Our educational detailers were also
trained to ask physicians, during both
initial and follow-up visits, how they and
their patients reacted to prescribing
recommendations. These queries often
led to identification of correctable ob¬
stacles. For example, discovering that
some physicians used propoxyphene as
an analgesic because of a lack of aware¬
ness of its risk/benefit attributes made
it possible to tailor educational materi¬
als to target these knowledge deficits.
Repetition and Reinforcement
Repetition of a few major points is
another technique often ignored in con¬
ventional continuing education that aids
in memory retention and promotes be¬
havior change.35,36 In a commercial de¬
tailing visit, a few principal advantages
of the product are likely to be repeated
several times during the detailing visit;
the product name itself is further im¬
printed in the physician's mind through
gifts from the manufacturer and adver¬
tisements with product identification.
While such approaches can be carried to
trivial extremes, there is some value to
such mnemonic devices. For example,
one "giveaway" we considered (but nev¬
er adopted) for our early study was a
free sample kit with the label "The Best
Antibiotic Therapy for Viral Upper
Respiratory Infections" emblazened
over a blister-pack whose unit-dose
cells were all empty. Rationale and evi¬
dence for these claims would appear on
the back of the package. This principle
of concentrating on a small number of
important messages is based on an un¬
derstanding that educational inter¬
changes successfully transmit but a few
points, no matter how complex the mes¬
sages being sent. This is equally true
with physicians, who have a hard
enough time keeping up with the clutter
of information deluge in a rapidly chang¬
ing medical practice. Attempting to
communicate too many or complex mes¬
sages often will fail to achieve retention
of the most important points. Graphic
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support with headlines, diagrams, and
photographs is an important compo¬
nent, exposing the physician to visual as
well as verbal presentation of the main
points.
Feedback of improved behavior with
reinforcement is another central compo¬
nent of effective detailing techniques
that can be used by noncommercial drug
information programs. Reinforcement
can occur when physicians discuss their
experiences with implementing recom¬
mended changes in prescribing behav¬
ior during follow-up visits. Detailers
can verbally encourage and applaud
their successes as well as discuss prob¬
lem cases and their resolution (eg, pa¬
tient demand). This principle is corrobo¬
rated by data that suggest that a
reinforcement visit was associated with
a twofold increase in the change in pre¬
scribing behavior in an educational
experiment.7
The commercial detailer may encour¬
age the physician to "try out" the prod¬
uct on his patients and to report back his
orher experiences at a subsequent visit,
often facilitating this with free samples.
If these experiences are positive, fur¬
ther discussion and positive reinforce¬
ment of the product ensue. However, it
is easy for such a "case study" approach
to cross over into pseudoscience. Some
pharmaceutical representatives will
pursue this strategy further by inviting
the physician to conduct a "study" of the
product in his or her own practice by
giving several patients the promoted
drug to compare with others who are
taking alternative treatments. In a de¬
scription ofa day spent with a successful
drug representative reported in the
Wall Street Journal (November 8,
1982:1, 25), a physician was encouraged
to conduct his own small-scale "clinical
trial" comparing one company's new
nonnarcotic analgesic with other pain
medications in patients: "Try it, com¬
pare it for yourself, you'll like it better."
This technique can set up an opportuni¬
ty to reinforce "positive clinical experi¬
ences" (possibly due to placebo effects)
in subsequent visits. Despite scientific
invalidity of such nonblinded, small-
scale trials in nonrandomized samples of
patients, this approach purports to ele¬
vate the office physician's status to the
level of clinical researcher, with all of its
positive connotations. Through the
drug to be marketed, the physician's
observations are equated with "sci¬
ence," further validating both the phy¬
sician and the drug.
In addition to such suspect approach¬
es, commercial detailers often employ
incentive strategies to reinforce desired
behavior.37 These incentives are direct¬
ed to all the actors involved: nurses or
Fig 2. —Educational material used in changing prescribing habits of a cephalosporin antibiotic. Pharmacoki-
netic considerations were emphasized over cost issues.
receptionists are given gifts to gain ac¬
cess to the physician; physicians are giv¬
en both gifts and free samples of the
drug; patients receive both samples and
educational pamphlets, also donated by
the detailer. One particularly offensive
use of incentives was the recent cam¬
paign by Ayerst, New York, NY, to
promote use of its brand of ß-blocker by
offering physicians "frequent prescrib-
er bonuses" for each patient prescribed
the product for whom a small reporting
form was completed. These could then
be traded in for free air travel in the
United States and to the Caribbean.
Brief Graphic Print Materials
Recent comprehensive reviews of
studies that evaluate a wide variety of
mailed continuing educational materi¬
als, including prescribing guidelines
and protocols, drug bulletins, commer¬
cially prepared brochures, and two-sid¬
ed "unadvertisements," have produced
little or no evidence supporting their
effectiveness in changing practice pat¬
terns when used alone.5,10 Nevertheless,
well-illustrated materials that empha¬
size the main clinical recommendations
in a straightforward way are important
adjuncts to face-to-face education that
can be mailed, posted, or inserted in
patient charts as well as used as a visual
device during detailing visits. Figure 2
gives an example of such an educational
pamphlet used at Beth Israel Hospital,
Boston, Mass, to reduce incorrect use of
the antibiotic cefazolin.20 The front cov¬
er of the monograph supports the pre¬
scribing change message in both head¬
lines and graphics; in addition, the
credibility provided by support ofhospi-
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tal experts and references to clinical
studies published in respected journals
are also presented prominently. It is
essential to pilot-test materials with
physicians who are similar to those in
the planned audience to be certain that
the content is actually received as
intended.
Figure 3 presents the front cover of
one of six unadvertisements used in a
controlled trial of a face-to-face educa¬
tional program to reduce excessive psy-
choactive drug use in nursing homes.
The headline and photograph promote a
gentle touch and "tucking in" of elderly
residents at bedtime as an alternative to
sedative use. On the reverse side, other
practical strategies for promoting sleep
are emphasized, such as avoiding day¬
time caffeine and napping, and increas¬
ing exercise and mobility. It also en¬
courages more careful selection and
dosing of sedatives if they are used.
Thorough references to the literature
are included. When such graphically il¬
lustrated data are referred to in face-to-
face sessions they can provide an inter¬
esting and salient respite from verbal
presentations and also involve the
prescribing physician in two-way
communication.
Offering Practical Alternatives
Behavioral science research in nu¬
merous domains documents that it is far
easier to get a subject to relinquish a
behavior if an alternative behavior is
proposed as a replacement, rather than
simple inaction. Thus, it is important to
offer the prescriber an alternative to the
practice being discouraged—either a
more rational medication choice or a
nonpharmacologic alternative. Phar¬
maceutical representatives ensure that
local pharmacies stock the alternative
drug recommended to replace specific
products prescribed by physicians. Sim¬
ilarly, it is important that academic de¬
tailing programs consider the practical¬
ity and availability of other treatments
to replace targeted drug therapies.
Nondrug alternative behaviors, in par¬
ticular, may be more difficult to achieve
if they require more time to implement.
Unfortunately, it may be easier and
more convenient for the busy physician
to prescribe a benzodiazepine than to
engage in a counseling session concern¬
ing the patient's family problems. On
the other hand, encouraging patients
with peripheral vascular insufficiency
to take short walks was a reasonably
actionable alternative to use of "periph¬
eral vasodilators" prescribed for this
condition.4 To help facilitate this behav¬
ior, a patient education pamphlet was
prepared as a physician "prescription"
of a specific exercise program, which
Fig 3.—Cover side of "unadvertisement" encouraging nursing home staff to substitute gentle touching and
reassurance of elderly residents at bedtime for sedative use.
could be tailored to the patient's physi¬
cal condition (Fig 1). For this approach
to be most effective, there should be no
financial disincentives to the patient
that act to discourage alternative treat¬
ments. For example, overuse of expen¬
sive prescription analgesics may be dif¬
ficult to reduce in a Medicaid program
that does not reimburse for recom¬
mended over-the-counter alternatives
such as aspirin or acetaminophen.
Selection and Training of
Academic Detailers
According to the pharmaceutical
marketing literature, commercial detail
people are selected on the basis of both
science background and potential for
sales,'* although in practice the latter
factor often predominates. There is no
standard requirement for any science
background, and often none exists.
Training is a crucial element in success¬
ful pharmaceutical marketing; it is also
the most carefully guarded. Hemminki
and Pesonen,14 in a survey of pharma¬
ceutical representatives in Europe, re¬
ported that the mean length of training
time before commencing detail work
was 14.3 weeks. This was divided be¬
tween sales techniques and a segment
on basic medical sciences and pharma¬
cology. Closed-circuit television and
role playing are common elements of
training used to perfect presentation
styles. In addition, fledgling represen¬
tatives may spend some time trying out
their presentations on groups of physi¬
cians. This approach is particularly use¬
ful in increasing the representative's
ability to answer questions convincingly
and to tailor the presentation to the par-
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ticular style of the physician. Fair trade
and advertising laws are emphasized as
they apply to the presentations.
Management control and feedback to
detail people are carried out principally
by district sales managers on the basis
of ongoing communications from detail¬
ers, including information contained in
required call reports as well as reports
of sales from pharmacies and in hospi¬
tals.38 Since representatives are gener¬
ally responsible for product sales in par¬
ticular geographic regions, companies
can track the amount of a given medica¬
tion sold in those areas to monitor repre¬
sentatives' sales performance. The
sales manager is also the key person in
providing emotional support to detail
people. Although most representatives
are salaried, the majority also receive
incentives for greater sales through
commissions and bonuses.
Based on reports in the medical mar¬
keting literature,13 most pharmaceutical
sales representatives probably make
between three and eight physician con¬
tacts per day. The contact time per visit
varies enormously, but an average of 5
to 8 minutes is a reasonable estimate of
average physician exposure time.13,19
Because of this limited time, most rep¬
resentatives rarely attempt to promote
more than two or, at most, three prod¬
ucts during one visit. One product usu¬
ally represents the major topic to which
most of the representative's time is
committed during the visit, with a sec¬
ondary drug covered "on the way out
the door."
In noncommercial community pro¬
grams, studies have documented the ef¬
fectiveness of clinical pharmacists both
with4 and without39 doctoral-level train¬
ing as well as consultant physicians.9
Both pharmacists and specially trained
physicians (eg, infectious disease spe¬
cialists) have been used in hospitals5;
more study is needed, however, on the
comparative cost-effectiveness of vari¬
ous personnel for particular problem ar¬
eas. Doctoral-level clinical pharmacists
who were primarily junior faculty in
schools ofpharmacy have been shown to
be effective as part-time, academically
based detailers.4"7 Because of their pre¬
vious training in pharmacology and
drug information, only about 2 days of
formal training was necessary for a pro¬
gram targeting three drugs. This fol¬
lowed self-study of a training manual
covering important clinical issues, im¬
portant principles of communication
and persuasion, and major recommen¬
dations concerning the target drugs and
their alternatives. In the training, vid¬
eotapes were shown of a former phar¬
maceutical representative detailing the
target drugs and their alternatives to a
physician-researcher (J.A.) who se¬
quentially acted the role of a resistant
and hostile physician, an indifferent
physician, and a receptive physician.
Following this, approximately a half
day was spent practicing on one anoth¬
er, with videotaped feedback. When the
pharmacist-educators and investiga¬
tors were satisfied that all trainees were
performing adequately, they pretested
theirpresentation on randomly selected
community physicians. These encoun¬
ters were discussed by telephone with
the project manager before actual de¬
tailing of study physicians began. In
general, these initial experiences indi¬
cated that physicians were more recep¬
tive than was expected based on the
experiences of commercial represent¬
atives.
After every physician visit, detailed
encounter forms were completed to as¬
sess physician receptivity, problems en¬
countered, methods of overcoming ob¬
stacles, call records, exposure times,
etc. These were reviewed periodically
by the project director (S.B.S.) to at¬
tempt to correct particularly difficult
problems experienced by some detail¬
ers. We found that the clinical pharma¬
cists needed only a minimal amount of
training and supervision to perform ad¬
equately in this function. This success
was evidenced by the prescribing data
outcomes: physicians reduced target
drug use by 14% compared with controls
after only two brief visits (P = .001).4
COMMENT
The long-standing effectiveness and
growth of pharmaceutical detailing in
recent decades illustrate that consider¬
able change in physician prescribingpractice is possible without regulatory
interventions. The behavioral science
literature and an increasing number of
field studies indicate that a number of
important principles of adult learning
and persuasion may be adaptable to
noncommercial programs designed to
improve clinical decision making.5,10
This is particularly important at a time
when powerful new agents are available
that have real toxic potential as well as
unique therapeutic effectiveness (eg,
isotretinoin). Regulation can ensure
that drugs with unacceptable risk/bene¬
fit relationships are not permitted to be
used, but no current regulatory appara¬
tus can ensure that marketed drugs are
prescribed intelligently. It should bepossible to take the best of these educa¬
tional approaches and put them at the
service of optimal care, while leaving
behind any techniques that are not in
keeping with the spirit ofprofessionally
based continuing medical education.
For example, one important structur-
al aspect of the commercial setting, but
not generally used in the not-for-profit
setting, is the provision of financial in¬
centives that reward pharmaceutical
representatives who achieve major pre¬
scribing changes that result in high
sales of their company's products (For¬
tune. October 1972:99-102). From the
perspective of many physicians, such
financial incentives probably reduce thedetailer's credibility and the perceived
objectivity of his claims concerning
product efficacy. In fact, these incen¬
tives have, on occasion, led to misinfor¬
mation by overzealous detailers.27,4042
This may be one reason that physicians
thus are reluctant to admit that their
prescribing decisions are influenced by
commercial representatives.16
The principles embodied in this ap¬
proach also conform with research con¬
ducted in the more general field of adult
education. For example, one synthesis
of this literature identified five condi¬
tions of adult learning: motivation to
change, active involvement of the learn¬
er, relevance to past experience, feed¬
back, and an informal atmosphere.43
Similarly, the extensive literature on
patient compliance also documents the
effectiveness of face-to-face educational
interactions and the general failure of
printed materials when used alone.44
This is particularly sobering in view of
the recently legislated "practice guide¬
lines" initiative that will be sponsored
by the US Department of Health and
Human Services and is intended to im¬
prove the use and outcomes of common
medical practices nationwide. If such
guidelines are not well integrated into
formal and informal person-to-person
educational programs they may not
have any practical value. In coming
years, it is likely that computer-baseddecision support systems will become
sophisticated and widespread enough
that some (but not all) of the interac¬
tions described above will be done elec¬
tronically. However, such capacity is
not likely to be available in most prac¬
tice settings in the immediate future.
Some may argue that restrictions and
regulations, rather than education, are
simpler and more effective strategies
for improving prescribing practice. In
fact, restrictive hospital formularies are
an effective means of reducing improper
use of some medications. However, for
many medications the problem is mis¬
use of an otherwise effective agent (eg,
antibiotics). Removing access to the
drug through a restrictive formulary or
reimbursement restrictions cannot ad¬
dress this issue. Further, drug restric¬
tions are not practical without effective
sanctions and enforcement. In addition,
no extensive literature exists on the ef-
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fectiveness of drug restrictions in com¬
munity settings, and the few extant
studies suggest that restrictions of one
drug can lead to generally inappropriate
use of substitute medications.5,45 Educa¬
tional approaches thus are more flexible
and adaptable in influencing most real-
world clinical decisions that do not fall
into neatly defined categories of correct
and incorrect practice.
The cost of new therapies is increas¬
ing sharply at the same time that pres¬
sure is escalating to control health care
costs. A small but important body of
research and practice has begun to
emerge based on the concept ofacadem¬
ic detailing that may present a rational
response to these pressures. Such edu¬
cational outreach activities by universi¬
ties, medical centers, and professional
associations are increasingly proposed
or being implemented under the spon¬
sorship of hospitals, public-sector
programs, health maintenance organi¬
zations, and other insurers. The appli¬
cability of this approach offers promise
to other areas beyond prescribing, such
as the use of blood products, laboratory
tests, and other diagnostic resources
and the decision to hospitalize. In this
way, improved precision in clinical deci¬
sion making can present an attractive
alternative to the twin extremes of un¬
acceptable costs and unacceptable
restriction.
This work was supported in part by the John A.
Hartford Foundation and the National Center for
Health Services Research (grants HS 03880 and HS
04933).
Figures 1 through 3 were reproduced with per¬
mission from Beth Israel Hospital, Boston, Mass.
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